- Home
- Publications
- Publication Search
- Publication Details
Title
The role of the interleukin (IL)-6/IL-6 receptor axis in cancer
Authors
Keywords
-
Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 46, Issue 6, Pages 1449-1462
Publisher
Portland Press Ltd.
Online
2018-11-23
DOI
10.1042/bst20180136
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment
- (2018) Hirotake Tsukamoto et al. CANCER RESEARCH
- Cancer-Associated Fibroblasts Affect Intratumoral CD8+and FoxP3+T Cells via Interleukin 6 in the Tumor Microenvironment
- (2018) Takuya Kato et al. CLINICAL CANCER RESEARCH
- The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling
- (2018) Paul Baran et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling
- (2018) Stefanie Schmidt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Interleukin-6: designing specific therapeutics for a complex cytokine
- (2018) Christoph Garbers et al. NATURE REVIEWS DRUG DISCOVERY
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
- (2018) Robert Q. Le et al. ONCOLOGIST
- Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells
- (2018) Jones Gyamfi et al. Scientific Reports
- Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice
- (2018) Asami Hanazawa et al. Frontiers in Immunology
- Abstract 4957: The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132
- (2018) Takenobu Nii et al. CANCER RESEARCH
- CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling
- (2017) C Lin et al. ONCOGENE
- YAP–IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis
- (2017) Koji Taniguchi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer
- (2017) Jun Zeng et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation
- (2017) Steffen Riethmueller et al. PLOS BIOLOGY
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value
- (2016) Jianwei Xu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
- (2016) Sylvia Heink et al. NATURE IMMUNOLOGY
- FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
- (2015) A. Deisseroth et al. CLINICAL CANCER RESEARCH
- Interleukin-6: Biology, signaling and strategies of blockade
- (2015) Fred Schaper et al. CYTOKINE & GROWTH FACTOR REVIEWS
- A gp130–Src–YAP module links inflammation to epithelial regeneration
- (2015) Koji Taniguchi et al. NATURE
- Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels
- (2015) Tomofumi Miura et al. PANCREAS
- Versatile functions for IL-6 in metabolism and cancer
- (2015) Jan Mauer et al. TRENDS IN IMMUNOLOGY
- The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis
- (2015) Qing Chang et al. NEOPLASIA
- Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance
- (2014) D. Gotthardt et al. BLOOD
- Interleukin-6: a villain in the drama of pancreatic cancer development and progression
- (2014) Reinhild Holmer et al. Hepatobiliary & Pancreatic Diseases International
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
- (2014) Frits van Rhee et al. LANCET ONCOLOGY
- The two faces of IL-6 in the tumor microenvironment
- (2014) Daniel T. Fisher et al. SEMINARS IN IMMUNOLOGY
- IL-6 in Inflammation, Immunity, and Disease
- (2014) T. Tanaka et al. Cold Spring Harbor Perspectives in Biology
- Revisiting the 1986 Molecular Cloning of Interleukin 6
- (2014) Toshio Hirano Frontiers in Immunology
- Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis
- (2013) Sohita Dhillon BIODRUGS
- The role of intratumoral and systemic IL-6 in breast cancer
- (2013) Christine Dethlefsen et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
- (2013) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
- (2013) R. Kurzrock et al. CLINICAL CANCER RESEARCH
- Complete Remission Achieved With Single Agent CNTO 328, an Anti–IL-6 Monoclonal Antibody, in Relapsed and Refractory Myeloma
- (2013) Ajai Chari et al. Clinical Lymphoma Myeloma & Leukemia
- Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma
- (2013) Simon M. Denley et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?
- (2013) S. J. C. van der Stegen et al. JOURNAL OF IMMUNOLOGY
- The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications—a review
- (2013) Antonio Macciò et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Impact of Interleukin-6 in Hematological Malignancies
- (2013) Renate Burger TRANSFUSION MEDICINE AND HEMOTHERAPY
- Role of interleukin-6 in stress, sleep, and fatigue
- (2012) Nicolas Rohleder et al. Annals of the New York Academy of Sciences
- Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells
- (2012) Yue Wang et al. CYTOKINE
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
- (2012) Stefan Rose-John International Journal of Biological Sciences
- Interleukin-6 - A Key Regulator of Colorectal Cancer Development
- (2012) Maximilian J. Waldner et al. International Journal of Biological Sciences
- Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy
- (2012) Chin Hao Chang et al. INTERNATIONAL JOURNAL OF CANCER
- Significance of the Correlation Between the Expression of Interleukin 6 and Clinical Features in Patients With Non-Small Cell Lung Cancer
- (2012) Eitetsu Koh et al. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
- Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
- (2011) S. I. Grivennikov et al. ANNALS OF THE RHEUMATIC DISEASES
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
- (2011) Marina Lesina et al. CANCER CELL
- Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
- (2011) K. Fizazi et al. EUROPEAN JOURNAL OF CANCER
- IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose transport in 3T3-L1 adipocytes
- (2011) Chenbo Ji et al. JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
- Soluble gp130 Regulates Prostate Cancer Invasion and Progression in an Interleukin-6 Dependent and Independent Manner
- (2011) Shahrokh F. Shariat et al. JOURNAL OF UROLOGY
- Interleukin-6: A multifunctional targetable cytokine in human prostate cancer
- (2011) Zoran Culig et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells
- (2011) S Yoon et al. ONCOGENE
- Endocrine Pancreas Development
- (2011) Eliete Dalla Corte Frantz et al. PANCREAS
- A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
- (2010) J-F Rossi et al. BRITISH JOURNAL OF CANCER
- Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells
- (2010) Yue Wang et al. CANCER LETTERS
- Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease
- (2010) Frits van Rhee et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum Interleukine-6 Concentration, But Not Interleukine-18, is Associated with Head and Neck Squamous Cell Carcinoma Progression
- (2010) Zahra Mojtahedi et al. PATHOLOGY & ONCOLOGY RESEARCH
- Inflammation and Cancer: IL-6 and STAT3 Complete the Link
- (2009) Jacqueline Bromberg et al. CANCER CELL
- Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
- (2009) Frédéric R Santer et al. ENDOCRINE-RELATED CANCER
- Interleukin-6 predicts recurrence and survival among head and neck cancer patients
- (2008) Sonia A. Duffy et al. CANCER
- STAT3 and STAT1 mediate IL-11–dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice
- (2008) Matthias Ernst et al. JOURNAL OF CLINICAL INVESTIGATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now